Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...

Delcath Systems (DCTH) announced the publication of a retrospective study by leading interventional radiologists and oncologists from Asklepios ...

In this study, researchers explored disparities in metastatic cutaneous melanoma survival following the introduction of immunotherapies.

Understand the rising rates of incurable prostate cancer in Canada and the importance of self-advocacy for testing.

A new study published in the Journal of Clinical Investigation has identified biomarkers that predict the likelihood of a patient developing checkpoint inhibitor-associated autoimmune diabetes before ...

Researchers in California have revealed how often cancers return and spread in the body among young cancer patients.

Lifileucel showed a 31.4% objective response rate and a median duration of response of 36.5 months in advanced melanoma patients. The median overall survival was 13.9 months, with adverse events ...

"If it is a melanoma and it's undiagnosed, it's going to continue to progress," said Dr. Abby Waldman, the medical director of the Mohs and Dermatologic Surgery Center at Brigham and Women's Hospital.

Discover why Ideaya Biosciences, Inc. is rated a Buy for its promising oncology pipeline and upcoming catalysts. Click for my ...

With $1.6 million from CPRIT, investigators are testing an endogenous T-cell therapy that has certain advantages over CAR ...

RP1 and nivolumab combination achieved a 32.9% objective response rate and 15.0% complete response rate in advanced melanoma patients post anti–PD-1 therapy failure. The treatment demonstrated durable ...

High blood pressure is often called a “silent” problem because it may not cause obvious symptoms at first, but over time it ...